Keeping Track: Orphan Drugs Aplenty At US FDA, From Pyrukynd Approval To Adagrasib Standard Review
Executive Summary
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
Keeping Track: Vijoice, Igalmi Approvals Show New Faces Of Older Drugs; Facility Change Extends Vutrisiran Goal
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Arimoclomol & Ipique Developers To Make Their Case For EU Approval
The sponsors of two investigational drugs that have previously experienced key regulatory setbacks are set to give oral explanations to the European Medicines Agency about why they believe their products should be approved in the EU.
Sanofi Posts More Positive Olipudase Alfa Data As Approval Decisions Loom
Ahead of a PDUFA date of 3 July, Sanofi has added to the body of clinical evidence supporting olipudase alfa as a treatment for acid sphingomyelinase deficiency (ASMD), a rare, progressive and potentially life-threatening disease with no approved therapies.